Literature DB >> 19903491

Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

James L Kreindler1.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel expressed in epithelial cells throughout the body. In the lungs, absence or dysfunction of CFTR results in altered epithelial salt and water transport eventuating in impaired mucociliary clearance, chronic infection and inflammation, and tissue damage. CF lung disease is the major cause of morbidity and mortality in CF despite the many therapies aimed at reducing it. However, recent technological advances combined with two decades of research driven by the discovery of the CFTR gene have resulted in the development and clinical testing of novel therapies aimed at the principal underlying defect in CF, thereby ushering in a new age of therapy for CF. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903491      PMCID: PMC2823951          DOI: 10.1016/j.pharmthera.2009.10.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  165 in total

1.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

Authors:  M L Drumm; D J Wilkinson; L S Smit; R T Worrell; T V Strong; R A Frizzell; D C Dawson; F S Collins
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

2.  Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.

Authors:  Maria P Limberis; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-22       Impact factor: 11.205

3.  Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.

Authors:  B Illek; L Zhang; N C Lewis; R B Moss; J Y Dong; H Fischer
Journal:  Am J Physiol       Date:  1999-10

Review 4.  Immunity to respiratory viruses.

Authors:  Jacob E Kohlmeier; David L Woodland
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 5.  Adeno-associated virus integration: virus versus vector.

Authors:  R H Smith
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

6.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

7.  Biochemical and biophysical identification of cystic fibrosis transmembrane conductance regulator chloride channels as components of endocytic clathrin-coated vesicles.

Authors:  N A Bradbury; J A Cohn; C J Venglarik; R J Bridges
Journal:  J Biol Chem       Date:  1994-03-18       Impact factor: 5.157

8.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study.

Authors:  R H Simon; J F Engelhardt; Y Yang; M Zepeda; S Weber-Pendleton; M Grossman; J M Wilson
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

9.  Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Authors:  Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

10.  Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ-domain-mediated interaction.

Authors:  V Raghuram; D O Mak; J K Foskett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

View more
  18 in total

1.  First cystic fibrosis drug advances towards approval.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

2.  Sensitivity of chloride efflux vs. transepithelial measurements in mixed CF and normal airway epithelial cell populations.

Authors:  Beate Illek; Dachuan Lei; Horst Fischer; Dieter C Gruenert
Journal:  Cell Physiol Biochem       Date:  2011-01-04

Review 3.  Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria.

Authors:  Jordi Camps; Isabel Pujol; Frederic Ballester; Jorge Joven; Josep M Simó
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

Review 4.  Emergent properties of proteostasis in managing cystic fibrosis.

Authors:  William E Balch; Daniela M Roth; Darren M Hutt
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

Review 5.  Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.

Authors:  Merouane Bencherif; Patrick M Lippiello; Rudolf Lucas; Mario B Marrero
Journal:  Cell Mol Life Sci       Date:  2010-10-15       Impact factor: 9.261

Review 6.  Pancreatic pathophysiology in cystic fibrosis.

Authors:  Katherine N Gibson-Corley; David K Meyerholz; John F Engelhardt
Journal:  J Pathol       Date:  2015-10-01       Impact factor: 7.996

7.  RACK1 interacts with filamin-A to regulate plasma membrane levels of the cystic fibrosis transmembrane conductance regulator.

Authors:  Laura Smith; Paul Litman; Ekta Kohli; Joseph Amick; Richard C Page; Saurav Misra; Carole M Liedtke
Journal:  Am J Physiol Cell Physiol       Date:  2013-05-01       Impact factor: 4.249

8.  Self-reactive CFTR T cells in humans: implications for gene therapy.

Authors:  Roberto Calcedo; Uta Griesenbach; Daniel J Dorgan; Samia Soussi; A Christopher Boyd; Jane C Davies; Tracy E Higgins; Stephen C Hyde; Deborah R Gill; J Alastair Innes; David J Porteous; Eric W Alton; James M Wilson; Maria P Limberis
Journal:  Hum Gene Ther Clin Dev       Date:  2013-07-19       Impact factor: 5.032

9.  Genetic testing: predictive value of genotyping for diagnosis and management of disease.

Authors:  Meral Ozgüç
Journal:  EPMA J       Date:  2011-05-06       Impact factor: 6.543

10.  Targeting protein-protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis.

Authors:  Isabel Devesa; Gregorio Fernández-Ballester; Antonio Ferrer-Montiel
Journal:  EMBO Mol Med       Date:  2013-08-27       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.